IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer
Highlights • Methyl jasmonate (MJ) has significant pro-apoptotic and anti-proliferative effects on endometrial cancer cells. • MJ inhibits the IGF1-induced IGF1R phosphorylation. • Inhibition of cell proliferation by MJ and IGF1R inhibitor involves PCNA and cyclin D1 downregulation. • Combination of...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2014-10, Vol.352 (2), p.214-219 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 219 |
|---|---|
| container_issue | 2 |
| container_start_page | 214 |
| container_title | Cancer letters |
| container_volume | 352 |
| creator | Bruchim, Ilan Sarfstein, Rive Reiss, Ari Flescher, Eliezer Werner, Haim |
| description | Highlights • Methyl jasmonate (MJ) has significant pro-apoptotic and anti-proliferative effects on endometrial cancer cells. • MJ inhibits the IGF1-induced IGF1R phosphorylation. • Inhibition of cell proliferation by MJ and IGF1R inhibitor involves PCNA and cyclin D1 downregulation. • Combination of MJ with IGF1R inhibitor has largely increased toxicity. |
| doi_str_mv | 10.1016/j.canlet.2014.06.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1553171249</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304383514003292</els_id><sourcerecordid>3402519891</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-5075298001bcde821d958dff9c4f29d17bee80f97539a3b6e1b2309390adb28c3</originalsourceid><addsrcrecordid>eNqFkV9rFDEUxYModq1-A5GAzzPe_NuZvAhSbC0UBG2fQyZzx810dlKTrHS-fTNsa8EXnwKXc87N-V1C3jOoGbDtp7F2dp4w1xyYrGFbAxMvyIa1Da8a3cJLsgEBshKtUCfkTUojACjZqNfkhEutGyn4hvy6vDhnP2heYkh-RnrrZ5uQ-nnnO59DpDjv7Oww0bxD6pYccrj3juIwoMs0DHSPebdMdLRpH2abV28x9aHMo7cTdas9viWvBjslfPf4npKb86_XZ9-qq-8Xl2dfrionmzZXChrFy-eBda7HlrNeq7YfBu3kwHXPmg6xhUE3Smgrui2yjgvQQoPtO946cUo-HnPvYvh9wJTNGA5xLisNU0qwhpXuRSWPKldqp4iDuYt-b-NiGJiVrhnNka5Z6RrYmkK32D48hh-6PfZ_TU84i-DzUYCl4h-P0STnsfTvfSy4TB_8_zb8G-AmP3tnp1tcMD13MYkbMD_XC68HZhJAcM3FA2MIok4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1553171249</pqid></control><display><type>article</type><title>IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Bruchim, Ilan ; Sarfstein, Rive ; Reiss, Ari ; Flescher, Eliezer ; Werner, Haim</creator><creatorcontrib>Bruchim, Ilan ; Sarfstein, Rive ; Reiss, Ari ; Flescher, Eliezer ; Werner, Haim</creatorcontrib><description>Highlights • Methyl jasmonate (MJ) has significant pro-apoptotic and anti-proliferative effects on endometrial cancer cells. • MJ inhibits the IGF1-induced IGF1R phosphorylation. • Inhibition of cell proliferation by MJ and IGF1R inhibitor involves PCNA and cyclin D1 downregulation. • Combination of MJ with IGF1R inhibitor has largely increased toxicity.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2014.06.013</identifier><identifier>PMID: 24997432</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Acetates - pharmacology ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Apoptosis ; Apoptosis - drug effects ; Breast cancer ; Cancer therapies ; Cell growth ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Cyclopentanes - pharmacology ; Cytotoxicity ; Dose-Response Relationship, Drug ; Endometrial cancer ; Endometrial carcinoma ; Endometrial Neoplasms - enzymology ; Endometrial Neoplasms - pathology ; Extracellular Signal-Regulated MAP Kinases - metabolism ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; IGF1 receptor (IGF1R) ; Insulin-like growth factor-1 (IGF1) ; Kinases ; Medical prognosis ; Methyl jasmonate ; NVP-AEW541 ; Oxylipins - pharmacology ; Phosphorylation ; Protein Kinase Inhibitors - pharmacology ; Proteins ; Proto-Oncogene Proteins c-akt - metabolism ; Pyrimidines - pharmacology ; Pyrroles - pharmacology ; Receptor, IGF Type 1 - antagonists & inhibitors ; Receptor, IGF Type 1 - metabolism ; Studies ; Time Factors ; Tumors ; Uterine serous carcinoma ; Women</subject><ispartof>Cancer letters, 2014-10, Vol.352 (2), p.214-219</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2014 Elsevier Ireland Ltd</rights><rights>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Oct 1, 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-5075298001bcde821d958dff9c4f29d17bee80f97539a3b6e1b2309390adb28c3</citedby><cites>FETCH-LOGICAL-c478t-5075298001bcde821d958dff9c4f29d17bee80f97539a3b6e1b2309390adb28c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.canlet.2014.06.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24997432$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bruchim, Ilan</creatorcontrib><creatorcontrib>Sarfstein, Rive</creatorcontrib><creatorcontrib>Reiss, Ari</creatorcontrib><creatorcontrib>Flescher, Eliezer</creatorcontrib><creatorcontrib>Werner, Haim</creatorcontrib><title>IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Highlights • Methyl jasmonate (MJ) has significant pro-apoptotic and anti-proliferative effects on endometrial cancer cells. • MJ inhibits the IGF1-induced IGF1R phosphorylation. • Inhibition of cell proliferation by MJ and IGF1R inhibitor involves PCNA and cyclin D1 downregulation. • Combination of MJ with IGF1R inhibitor has largely increased toxicity.</description><subject>Acetates - pharmacology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Cell growth</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Cyclopentanes - pharmacology</subject><subject>Cytotoxicity</subject><subject>Dose-Response Relationship, Drug</subject><subject>Endometrial cancer</subject><subject>Endometrial carcinoma</subject><subject>Endometrial Neoplasms - enzymology</subject><subject>Endometrial Neoplasms - pathology</subject><subject>Extracellular Signal-Regulated MAP Kinases - metabolism</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>IGF1 receptor (IGF1R)</subject><subject>Insulin-like growth factor-1 (IGF1)</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Methyl jasmonate</subject><subject>NVP-AEW541</subject><subject>Oxylipins - pharmacology</subject><subject>Phosphorylation</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Proteins</subject><subject>Proto-Oncogene Proteins c-akt - metabolism</subject><subject>Pyrimidines - pharmacology</subject><subject>Pyrroles - pharmacology</subject><subject>Receptor, IGF Type 1 - antagonists & inhibitors</subject><subject>Receptor, IGF Type 1 - metabolism</subject><subject>Studies</subject><subject>Time Factors</subject><subject>Tumors</subject><subject>Uterine serous carcinoma</subject><subject>Women</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkV9rFDEUxYModq1-A5GAzzPe_NuZvAhSbC0UBG2fQyZzx810dlKTrHS-fTNsa8EXnwKXc87N-V1C3jOoGbDtp7F2dp4w1xyYrGFbAxMvyIa1Da8a3cJLsgEBshKtUCfkTUojACjZqNfkhEutGyn4hvy6vDhnP2heYkh-RnrrZ5uQ-nnnO59DpDjv7Oww0bxD6pYccrj3juIwoMs0DHSPebdMdLRpH2abV28x9aHMo7cTdas9viWvBjslfPf4npKb86_XZ9-qq-8Xl2dfrionmzZXChrFy-eBda7HlrNeq7YfBu3kwHXPmg6xhUE3Smgrui2yjgvQQoPtO946cUo-HnPvYvh9wJTNGA5xLisNU0qwhpXuRSWPKldqp4iDuYt-b-NiGJiVrhnNka5Z6RrYmkK32D48hh-6PfZ_TU84i-DzUYCl4h-P0STnsfTvfSy4TB_8_zb8G-AmP3tnp1tcMD13MYkbMD_XC68HZhJAcM3FA2MIok4</recordid><startdate>20141001</startdate><enddate>20141001</enddate><creator>Bruchim, Ilan</creator><creator>Sarfstein, Rive</creator><creator>Reiss, Ari</creator><creator>Flescher, Eliezer</creator><creator>Werner, Haim</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20141001</creationdate><title>IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer</title><author>Bruchim, Ilan ; Sarfstein, Rive ; Reiss, Ari ; Flescher, Eliezer ; Werner, Haim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-5075298001bcde821d958dff9c4f29d17bee80f97539a3b6e1b2309390adb28c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Acetates - pharmacology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Cell growth</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Cyclopentanes - pharmacology</topic><topic>Cytotoxicity</topic><topic>Dose-Response Relationship, Drug</topic><topic>Endometrial cancer</topic><topic>Endometrial carcinoma</topic><topic>Endometrial Neoplasms - enzymology</topic><topic>Endometrial Neoplasms - pathology</topic><topic>Extracellular Signal-Regulated MAP Kinases - metabolism</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>IGF1 receptor (IGF1R)</topic><topic>Insulin-like growth factor-1 (IGF1)</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Methyl jasmonate</topic><topic>NVP-AEW541</topic><topic>Oxylipins - pharmacology</topic><topic>Phosphorylation</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Proteins</topic><topic>Proto-Oncogene Proteins c-akt - metabolism</topic><topic>Pyrimidines - pharmacology</topic><topic>Pyrroles - pharmacology</topic><topic>Receptor, IGF Type 1 - antagonists & inhibitors</topic><topic>Receptor, IGF Type 1 - metabolism</topic><topic>Studies</topic><topic>Time Factors</topic><topic>Tumors</topic><topic>Uterine serous carcinoma</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bruchim, Ilan</creatorcontrib><creatorcontrib>Sarfstein, Rive</creatorcontrib><creatorcontrib>Reiss, Ari</creatorcontrib><creatorcontrib>Flescher, Eliezer</creatorcontrib><creatorcontrib>Werner, Haim</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bruchim, Ilan</au><au>Sarfstein, Rive</au><au>Reiss, Ari</au><au>Flescher, Eliezer</au><au>Werner, Haim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2014-10-01</date><risdate>2014</risdate><volume>352</volume><issue>2</issue><spage>214</spage><epage>219</epage><pages>214-219</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>Highlights • Methyl jasmonate (MJ) has significant pro-apoptotic and anti-proliferative effects on endometrial cancer cells. • MJ inhibits the IGF1-induced IGF1R phosphorylation. • Inhibition of cell proliferation by MJ and IGF1R inhibitor involves PCNA and cyclin D1 downregulation. • Combination of MJ with IGF1R inhibitor has largely increased toxicity.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>24997432</pmid><doi>10.1016/j.canlet.2014.06.013</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2014-10, Vol.352 (2), p.214-219 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_journals_1553171249 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Acetates - pharmacology Antineoplastic Combined Chemotherapy Protocols - pharmacology Apoptosis Apoptosis - drug effects Breast cancer Cancer therapies Cell growth Cell Line, Tumor Cell Proliferation - drug effects Cyclopentanes - pharmacology Cytotoxicity Dose-Response Relationship, Drug Endometrial cancer Endometrial carcinoma Endometrial Neoplasms - enzymology Endometrial Neoplasms - pathology Extracellular Signal-Regulated MAP Kinases - metabolism Female Hematology, Oncology and Palliative Medicine Humans IGF1 receptor (IGF1R) Insulin-like growth factor-1 (IGF1) Kinases Medical prognosis Methyl jasmonate NVP-AEW541 Oxylipins - pharmacology Phosphorylation Protein Kinase Inhibitors - pharmacology Proteins Proto-Oncogene Proteins c-akt - metabolism Pyrimidines - pharmacology Pyrroles - pharmacology Receptor, IGF Type 1 - antagonists & inhibitors Receptor, IGF Type 1 - metabolism Studies Time Factors Tumors Uterine serous carcinoma Women |
| title | IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T08%3A13%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IGF1R%20tyrosine%20kinase%20inhibitor%20enhances%20the%20cytotoxic%20effect%20of%20methyl%20jasmonate%20in%20endometrial%20cancer&rft.jtitle=Cancer%20letters&rft.au=Bruchim,%20Ilan&rft.date=2014-10-01&rft.volume=352&rft.issue=2&rft.spage=214&rft.epage=219&rft.pages=214-219&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2014.06.013&rft_dat=%3Cproquest_cross%3E3402519891%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1553171249&rft_id=info:pmid/24997432&rft_els_id=S0304383514003292&rfr_iscdi=true |